German biopharma: Economic data and benefit for patients with autoimmune diseases

1 July 2019

The new biotechnology report describing the situation of medical biotechnology in Germany is now available on the website of the German trade group the VFA.

It was provided by Boston Consulting Group for vfa bio. This yearly report is the only one recording all activities within medical biotechnology in Germany – ranging from start-up to big companies. In addition to key economic data on medical biotechnology in Germany in 2018, the focus of this year’s report is on the benefit of biopharmaceuticals for patients with autoimmune diseases.

Key economic data on medical biotechnology in Germany in 2018 at a glance:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK